Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial

BACKGROUND: With the expanded utilization of transcatheter aortic valve implantation (TAVI) to younger and lower surgical risk patients with severe aortic stenosis (AS), optimal medical therapy after TAVI procedure has become the main concern. Renin-angiotensin system inhibitors (RASi) are widely ut...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yan Biao, Xia, Congying, Cheng, Yiheng, Li, Qiao, Wei, Xin, Ou, Yuanweixiang, Chen, Fei, Li, Yijian, Liu, Qi, Xiong, Tianyuan, Zhao, Zhengang, Peng, Yong, Wei, Jiafu, Feng, Yuan, Chen, Mao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286566/
https://www.ncbi.nlm.nih.gov/pubmed/34275476
http://dx.doi.org/10.1186/s13063-021-05411-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286566/
https://www.ncbi.nlm.nih.gov/pubmed/34275476
http://dx.doi.org/10.1186/s13063-021-05411-5

Ejemplares similares